LoginRegister

    Granules India arm wins USFDA approval for stimulant drug Amphetamine Sulfate tablets

    Medical Dialogues BureauWritten by Medical Dialogues Bureau   |  

    Amphetamine Sulfate tablets is a generic version of Arbor Pharmaceuticals LLC's Evekeo tablets in similar strength, it added.


    New Delhi: Drug firm Granules India on Tuesday said its US arm has received approval from the USFDA for a generic central nervous system stimulant drug, Amphetamine Sulfate tablets.


    The US Food & Drug Administration (USFDA) has approved the abbreviated new drug application (ANDA) filed by the company's subsidiary, Granules Pharmaceuticals Inc, for Amphetamine Sulfate tablets USP 5 mg and 10 mg, Granules India said in a filing to BSE.


    The product is a generic version of Arbor Pharmaceuticals LLC's Evekeo tablets in similar strength, it added.


    Read Also: Granules India completes USFDA inspection for Bonthapally facility with one observation


    "Amphetamine Sulfate tablets is a central nervous system stimulant used to treat a sleep disorder, increase attention, decrease impulsiveness and hyperactivity in patients with Attention Deficit Hyperactivity Disorder (ADHD)," Granules India said.


    Read Also: Granules India gets USFDA nod for Methylphenidate Hydrochloride ER capsules

    Abbreviated New Drug ApplicationADHAAmphetamine Sulfate tabletsANDAArbor PharmaArbor Pharmaceuticalsattention deficit hyperactivity disorderEvekeo tabletsgeneric central nervous systemGranules IndiaGranules PharmaceuticalsGranules Pharmaceuticals Incimpulsivenesspharmapharma newspharma news indiasleep disorderstimulant drugUSFDA nod
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X